iCAD (NASDAQ:ICAD) Stock Rating Upgraded by StockNews.com

iCAD (NASDAQ:ICAD) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

iCAD Stock Performance

NASDAQ:ICAD opened at $2.14 on Wednesday. iCAD has a 52-week low of $1.18 and a 52-week high of $3.78. The company has a market cap of $56.80 million, a price-to-earnings ratio of -16.46 and a beta of 1.95. The firm’s 50-day moving average is $2.68 and its 200-day moving average is $2.08.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The firm had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.72 million.

Institutional Investors Weigh In On iCAD

A number of large investors have recently bought and sold shares of the business. waypoint wealth counsel raised its stake in shares of iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the last quarter. Thompson Davis & CO. Inc. bought a new position in iCAD in the 4th quarter worth approximately $31,000. PKS Advisory Services LLC acquired a new position in iCAD during the 4th quarter worth $53,000. Wells Fargo & Company MN boosted its position in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of iCAD in the 4th quarter valued at $92,000. 24.61% of the stock is currently owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.